Crohn’s Disease Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Anti-inflammatory, Immune System Suppressors, Antibiotics, Surgical), By Region, And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Methodology & Scope
                  1.1. Research Methodology
                  1.2. Research Scope & Assumptions
                  1.3. List of Data Sources
Chapter 2. Executive Summary
                  2.1. Market Snapshot
Chapter 3. Crohn’s Disease Therapeutics Industry Outlook
                  3.1. Market segmentation
                  3.2. Market size and growth prospects, 2014 - 2025
                  3.3. Value chain analysis
                  3.4. Regulatory Framework
                  3.5. Market dynamics
                      3.5.1. Market driver analysis
                      3.5.2. Market restraint analysis
                  3.6. Key opportunities prioritized
                  3.7. Industry analysis - Porter's
                  3.8. PESTEL analysis, 2016
Chapter 4. Crohn’s Disease Therapeutics: Therapy Type Outlook
                  4.1. Crohn’s disease therapeutics market share by therapy type, 2014 & 2025 (USD Billion)
                  4.2. Non-Surgical
                      4.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
                      4.2.2. Market estimates and forecast by region, 2014 - 2025 (USD Billion)
                  4.3. Surgical
                      4.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
                      4.3.2. Market estimates and forecast by region, 2014 - 2025 (USD Billion)
Chapter 5. Crohn’s Disease Therapeutics Market: Regional Outlook
                  5.1. Crohn’s disease therapeutics market share by region, 2015 & 2025 (USD Billion)
                  5.2. North America
                      5.2.1. North America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.2.2. U.S.
                          5.2.2.1. U.S. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.2.3. Canada
                          5.2.3.1. Canada Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                  5.3. Europe
                      5.3.1. Europe Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.3.2. U.K.
                          5.3.2.1. U.K. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.3.3. Germany
                          5.3.3.1. Germany Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                  5.4. Asia Pacific
                      5.4.1. Asia Pacific Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.4.2. China
                          5.4.2.1. China Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.4.3. India
                          5.4.3.1. India Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.4.4. Japan
                          5.4.4.1. Japan Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                  5.5. Latin America
                      5.5.1. Latin America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.5.2. Brazil
                          5.5.2.1. Brazil Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.5.3. Mexico
                          5.5.3.1. Mexico Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                  5.6. Middle East & Africa
                      5.6.1. MEA Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
                      5.6.2. South Africa
                          5.6.2.1. South Africa Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
Chapter 6. Competitive Landscape
                  6.1. Strategy Framework
                  6.2. Market Participation Categorization
Chapter 7. Company Profiles
                  7.1. Takeda Pharmaceutical Company Limited
                      7.1.1. Company Overview
                      7.1.2. Financial Performance
                      7.1.3. Product Benchmarking
                      7.1.4. Strategic Initiatives
                  7.2. Allergan Inc.
                      7.2.1. Company Overview
                      7.2.2. Financial Performance
                      7.2.3. Product Benchmarking
                      7.2.4. Strategic Initiatives
                  7.3. Perrigo Company PLC
                      7.3.1. Company Overview
                      7.3.2. Financial Performance
                      7.3.3. Product Benchmarking
                      7.3.4. Strategic Initiatives
                  7.4. Pfizer Inc.
                      7.4.1. Company Overview
                      7.4.2. Financial Performance
                      7.4.3. Product Benchmarking
                      7.4.4. Strategic Initiatives
                  7.5. Johnson & Johnson Services Inc.
                      7.5.1. Company Overview
                      7.5.2. Financial Performance
                      7.5.3. Product Benchmarking
                      7.5.4. Strategic Initiatives
                  7.6. Janssen Biotech Inc.
                      7.6.1. Company Overview
                      7.6.2. Financial Performance
                      7.6.3. Product Benchmarking
                      7.6.4. Strategic Initiatives
                  7.7. Ferring B.V.
                      7.7.1. Company Overview
                      7.7.2. Financial Performance
                      7.7.3. Product Benchmarking
                      7.7.4. Strategic Initiatives
                  7.8. Celgene Corporation
                      7.8.1. Company Overview
                      7.8.2. Financial Performance
                      7.8.3. Product Benchmarking
                      7.8.4. Strategic Initiatives
                  7.9. Genentech Inc.
                      7.9.1. Company Overview
                      7.9.2. Financial Performance
                      7.9.3. Product Benchmarking
                      7.9.4. Strategic Initiatives
                  7.10. Salix Pharmaceuticals
                      7.10.1. Company Overview
                      7.10.2. Financial Performance
                      7.10.3. Product Benchmarking
                      7.10.4. Strategic Initiatives
                  7.11. UCB S.A.
                      7.11.1. Company Overview
                      7.11.2. Financial Performance
                      7.11.3. Product Benchmarking
                      7.11.4. Strategic Initiatives
                  7.12. AbbVie Inc.
                      7.12.1. Company Overview
                      7.12.2. Financial Performance
                      7.12.3. Product Benchmarking
                      7.12.4. Strategic Initiatives
                  7.13. Gilead Sciences Inc.
                      7.13.1. Company Overview
                      7.13.2. Financial Performance
                      7.13.3. Product Benchmarking
                      7.13.4. Strategic Initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2015 - 2025 (USD Billion)
TABLE 3 U.S. Crohn’s disease therapeutic market estimates and forecasts, therapy type, 2014 - 2025 (USD Billion)
TABLE 4 Canada Crohn’s disease therapeutic market estimates and forecasts, therapy type, 2014 - 2025 (USD Billion)
TABLE 5 Europe Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 6 U.K. Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 7 Germany Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 8 Asia Pacific Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 9 Japan Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 10 China Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 11 India Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 12 Latin America Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 13 Brazil Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 14 Mexico Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 15 MEA Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)
TABLE 16 South Africa Crohn’s disease therapeutic market estimates and forecasts, by therapy type, 2014 - 2025 (USD Billion)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary
FIG. 6 Market trends &outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Crohn’s disease therapeutics pipeline
FIG. 10 Market restraint relevance analysis (Current & future impact)
FIG. 11 Penetration & growth prospect mapping
FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Crohn’s disease therapeutic market Therapy type outlook key takeaways
FIG. 15 Crohn’s disease therapeutic market: Type movement analysis
FIG. 16 Global non-surgical market, 2014 - 2025 (USD Billion)
FIG. 17 Global Anti-inflammatory drugs market, 2014 - 2025 (USD Billion)
FIG. 18 Global Immune system suppressors market, 2014 - 2025 (USD Billion)
FIG. 19 Global Antibiotics market, 2014 - 2025 (USD Billion)
FIG. 20 Global other medications market, 2014 - 2025 (USD Billion)
FIG. 21 Global Surgical market, 2014 - 2025 (USD Billion)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Regional outlook, 2015 & 2024
FIG. 24 North America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 25 U.S. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 26 Canada Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 27 Europe Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 28 U.K. Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 29 Germany Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 30 Asia Pacific Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 31 Japan Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 32 China Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 33 India Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 34 Latin America Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 35 Brazil Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 36 Mexico Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 37 MEA Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 38 South Africa Crohn’s disease therapeutic market, 2014 - 2025 (USD Billion)
FIG. 39 Strategy framework
FIG. 40 Participant categorization